Insider Transactions in Q2 2024 at Ultragenyx Pharmaceutical Inc. (RARE)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 18
2024
|
Daniel G Welch |
BUY
Grant, award, or other acquisition
|
Direct |
5,345
+16.55%
|
-
|
|
Jun 18
2024
|
Matthew K Fust |
BUY
Grant, award, or other acquisition
|
Direct |
5,345
+20.92%
|
-
|
|
Jun 18
2024
|
Deborah Dunsire |
BUY
Grant, award, or other acquisition
|
Direct |
5,345
+17.57%
|
-
|
|
Jun 18
2024
|
Shehnaaz Suliman |
BUY
Grant, award, or other acquisition
|
Direct |
5,345
+20.92%
|
-
|
|
Jun 18
2024
|
Corazon (Corsee) D. Sanders |
BUY
Grant, award, or other acquisition
|
Direct |
5,345
+29.8%
|
-
|
|
Jun 18
2024
|
Amrit Ray |
BUY
Grant, award, or other acquisition
|
Direct |
5,345
+23.27%
|
-
|
|
Jun 18
2024
|
Michael Narachi |
BUY
Grant, award, or other acquisition
|
Direct |
5,345
+16.55%
|
-
|
|
Jun 12
2024
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,806
-14.47%
|
$441,270
$45.0 P/Share
|
|
Jun 10
2024
|
Corazon (Corsee) D. Sanders |
SELL
Open market or private sale
|
Direct |
1,737
-19.33%
|
$71,217
$41.1 P/Share
|
|
May 02
2024
|
Eric Crombez EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
354
-0.73%
|
$15,222
$43.66 P/Share
|
|
Apr 18
2024
|
Eric Crombez EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
142
-0.29%
|
$6,248
$44.1 P/Share
|
|
Apr 16
2024
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14
-0.03%
|
$588
$42.31 P/Share
|